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Abstract 
Background: In the 1990s, azithromycin became the drug of choice for many infectious diseases but emerging 
resistance to the drug has only been reported in the last decade. In the last 5 years, the National Neisseria gonorrhoeae 
Reference Laboratory of Hungary (NNGRLH) has also observed an increased number of N. gonorrhoeae strains resist‑
ant to azithromycin. The aim of this study was to determine the most frequent sequence types (ST) of N. gonorrhoeae 
related to elevated levels of azithromycin MIC (minimal inhibitory concentration). Previously and currently isolated 
azithromycin‑resistant strains have been investigated for the existence of molecular relationship.
Methods: Maldi‑Tof technic was applied for the identification of the strains isolated from outpatients attending the 
reference laboratory. Testing antibiotic susceptibility of azithromycin, cefixime, ceftriaxone, tetracycline, spectinomycin 
and ciprofloxacin was carried out for all the identified strains, using MIC strip test Liofilchem®. N. gonorrhoeae multian‑
tigen sequence typing (NG‑MAST) was performed exclusively on azithromycin‑resistant isolates. A phylogenetic tree 
was drawn using MEGA6 (Molecular Evolutionary Genetics Analysis Version 6.0) Neighbour‑Joining method.
Results: Out of 192 N. gonorrhoeae isolates, 30.0 % (58/192) proved resistant to azithromycin (MIC > 0.5 mg/L). Of 
the azithromycin‑resistant isolates, ST1407, ST4995 and ST11064 were the most prevalent. Based on the phylogenetic 
analysis, the latter two STs are closely related.
Conclusions: In contrast to West‑European countries, in our region, resistance to azithromycin has increased up to 
30 % in the last 5 years, so the recommendation of the European Guideline −500 mg of ceftriaxone combined with 
2 g of azithromycin as first choice therapy against N. gonorrhoeae‑ should be seriously considered in case of Hungary.
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Background
The treatment of gonorrhoea infection poses a continu-
ous problem as Neisseria gonorrhoeae has developed 
resistance to each antimicrobials used in the past 70 years 
[1]. Therefore, it is necessary to enhance the surveil-
lance of gonococcal antimicrobial resistance, especially 
for the drugs of first choice: ceftriaxone and azithromy-
cin [2]. In Hungary, resistance to ceftriaxone has not yet 
been reported. In contrast, the appearance and spread of 
azithromycin-resistance have been observed in the last 
4 years [3].
Since the 1990s, azithromycin has become the drug of 
choice for many infections, such as sexually transmitted 
diseases (STDs), community-acquired pneumonia, acute 
bacterial sinusitis, otitis media, tonsillitis, pharyngitis, 
skin infections or acute bacterial exacerbations of chronic 
obstructive pulmonary disease [4]. Of STDs, azithromy-
cin is used to treat uncomplicated gonorrhoea in patients 
with cephalosporin allergy, Chlamydia trachomatis co-
infection, Heamophilus ducreyii, Ureaplasma urealyti-
cum, Mycoplasma genitalium infections. This antibiotic 
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revolutionised the therapy as it shortened treatment time 
from 7–14 days to 1–5 days and improved patient com-
pliance due to high tissue levels and long half-life. New 
administration formulations such as sustained-release 
microspheres allowed higher doses to be administered 
and reduced gastrointestinal side-effects, so azithromy-
cin seemed to be capable of approaching the concept of 
an ideal antibiotic [5]. However, recently decreased anti-
microbial susceptibility to azithromycin may disprove 
this assumption.
According to the data of the European Surveillance of 
Antimicrobial Consumption (ESAC), in Hungary the out-
patient consumption of antimicrobials was 16.0 defined 
daily doses (DDD) per 1000 inhabitants per day. This 
number can be subdivided into major antibiotic classes 
such as penicillins topping the list by DDD of 7.19, mac-
rolides taking the second place with DDD of 2.94 and, 
finally, cephalosporins with DDD of 2.13 [6].
Nevertheless, at the National Neisseria gonorrhoeae 
Reference Laboratory of Hungary (NNGRLH), we 
observed the appearance and rapid spread of azithromy-
cin-resistance in Hungary between 2010 and 2013. We 
aimed to survey the antimicrobial susceptibility in 2014 
and compare it with the data of the last 4 years and char-
acterise the azithromycin-resistant strains by NG-MAST.
Molecular evolutionary analysis was conducted and 
genetic relationships were estimated between the STs 
spreading in Hungary in 2014.
Methods
Bacterial strains and medical records
The NNGRLH at the STD Centre in the Department of 
Dermatology, Venerology and Dermatooncology of Sem-
melweis University, Budapest, Hungary collected samples 
from consecutive symptomatic gonorrhoea patients and 
from their asymptomatic contacts in 2014. The samples 
were cultured, characterised and stored on Cryobank 
breads (Mast Diagnostic, Germany) at −80  °C. Clinical 
data such as sex, age, sexual orientation, anatomic site of 
infection were recorded. C. trachomatis co-infection was 
also screened. Patients’ data were analysed according to 
law 1997/CLIV 26§ taking into account maximum pri-
vacy rights and anonymity of patients [7].
Antibiotic susceptibility
Clinical samples -cervical, anal, urethral and pharyngeal 
swabs- were obtained and grown on preheated VCA3 
agar (Biomérieux, Budapest, Hungary) and on non-selec-
tive PVX chocolate agar (Biomérieux, Budapest, Hun-
gary) at 37 °C in an atmosphere of 5 % of carbon dioxide 
for 24–48  h. Minimum inhibitory concentrations (MIC; 
mg/L) were determined for azithromycin, cefixime, cef-
triaxone, tetracycline, spectinomycin and ciprofloxacin 
on PVX chocolate agar (Biomérieux, Budapest, Hun-
gary) using MIC strip tests (Liofilchem® s.r.l., Roseto 
degli Abruzzi, Italy) according to the manufacturer’s 
instructions, using a direct colony suspension equivalent 
to McFarland standard of 0.5. Testing conditions also 
included incubation at 36.5  °C and 5  % of carbon diox-
ide for 24 h. All results were interpreted by using break-
points for susceptibility and resistance according to the 
European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) [8]. Concerning the MIC breakpoints 
of azithromycin, strains with MICs over 0.25  mg/L but 
below 0.5  mg/L were considered to be of intermediate 
resistance. Isolates with MICs higher than 0.5 mg/L were 
considered resistant. N. gonorrhoeae ATCC 49226, with 
an azithromycin MIC of 0.12 mg/L, was used as a control 
strain to ensure the quality of the susceptibility tests.
Molecular methods
Out of the 58 resistant and 42 intermediately resist-
ant strains 29 and 21 were selected for N. gonorrhoeae 
multiantigen sequence typing (NG-MAST) according 
to a previously described method [9]. The sequences of 
porB and tbpB PCR products were determined after their 
preliminary purification by the Exosap IT purification 
kit (Affymetrix, USA). BigDye® Terminator v3.1 Cycle 
Sequencing Kit (Life Technologies, USA) was used and 
the same forward and reverse primers were applied as 
for porB and tbpB PCR methods. Last purification was 
carried out by NucleoSEQ Column PCR Purification 
Kit (Macherey–Nagel, Germany). Nucleotide sequences 
were determined by capillary electrophoresis, with a cap-
illary length of 50 cm and POP-7 polymer on ABI 3130xl 
Genetic Analyzer (Applied Biosystems, Foster City, CA, 
USA).
NG-MAST STs including the new alleles and STs were 
assigned on the NG-MAST website (www.ng-mast.net).
Phylogenetic tree was constructed by MEGA6 (Molec-
ular Evolutionary Genetics Analysis Version 6.0) Neigh-
bour-Joining algorithm, using maximum composite 
likelihood model [10]. The degree of similarity was deter-
mined using the highly similar sequence (Megablast) 
BLASTN Program of the National Library of Medicine of 
the National Center for Biotechnology Information [11].
Results
In 2014, 192 N. gonorrhoeae strains were isolated at the 
STD Centre of the Department of Dermatology, Ven-
erology and Dermatooncology of Semmelweis University, 
Budapest, Hungary. The number of patients attending 
our STD centre makes up about 10 % of the total num-
ber of notified gonorrhoea infections in Hungary year 
by year. However, the ratio of N. gonorrhoeae positive 
patients to total patients examined increased from 7.8 % 
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in 2013 to 10.85 % by the end of 2014. Of the 192 N. gon-
orrhoeae, 85 % were isolated from male patients (median 
age 32 years); the remaining strains were collected from 
females (median age 26 years).
Urethritis was found in 77.3 % of male patients, while in 
females the dominant anatomical site of infection was the 
urethra (68.9 %) and cervix (65.5 %). Symptomatic infec-
tions or asymptomatic carrier states were detected in the 
anus (20.2 %/44.8 %) and in the pharynx (17.9 %/24.1 %) 
in male/female patients, respectively.
All the 192 isolates were susceptible to ceftriaxone 
and spectinomycin. The prevalence of ciprofloxacin and 
tetracycline resistance −39.8 and 70  %, respectively- 
remained as high as in previous years in Hungary. How-
ever, the MIC averages of ceftriaxone and cefixime have 
increased in the last few years. Cefixime MIC exceeded 
the resistant breakpoints in 1.57 % of the strains.
Of the 192 strains, 92 (48  %) were susceptible to 
azithromycin and 100 (52  %) exhibited reduced suscep-
tibility. Fifty-eight of these 100 strains −30.0 % of all the 
strains- were resistant to azithromycin, according to the 
breakpoints of EUCAST. The percentage of azithromycin 
resistance showed a significant increase from 15.9  % in 
2013 to 30.0 % in 2014 (χ2 = 11.4437, P value is 0.000717, 
P < 0.001). Concerning the strains with reduced suscepti-
bility to azithromycin, we can say that the ratio of female/
male patients was 1–7.3. MICs of ≥1  mg/L for azithro-
mycin were observed in 7.0 % (13/192) of the isolated N. 
gonorrhoeae strains out of which three had an MIC of 
1.5 mg/L (Additional file 1: Figure S1).
The prevalence of C. trachomatis infection detected 
by multiplex RT-PCR was only 6.7  % in 2014 at the 
NNGRLH, but N. gonorrhoeae positivity was found in 
12.2 % of cases. Only 14.7 % of the gonorrhoea-positive 
samples were co-infected with C. trachomatis.
The 50 N. gonorrhoeae resistant or intermediate-
resistant isolates to azithromycin were divided into 34 
NG-MAST sequence types, and a unique NG-MAST 
sequence type was found for 10 isolates. The three domi-
nant strains were ST1407, ST4995 and ST11064, each 
represented by 5 isolates (10–10 %). Regarding frequency, 
these were followed by ST 4417 represented by 3 iso-
lates, then by ST 995 and ST 8517, each represented by 
2 isolates. The 29 other STs were represented by only 
one isolate. Ten new STs, which had not been previously 
described in the world, were assigned as ST 11699 to ST 
11708 on NG-MAST website. Four of them, ST 11703, 
11706-11708, due to new allele combinations of known 
porB and tbpB alleles, were assigned on the website. The 
other 6 new STs had new porB or tbpB alleles (Table 1).
According to the phylogenic tree in Fig. 1, the azithro-
mycin-resistant and intermediately resistant strains iso-
lated in NNGLRH in 2014 were divided into three major 
groups based on closer relationship. From the most 
prevalent STs, the first group contained ST225; ST1407 
belonged to the second group, whereas the third group 
contained ST4995 and ST11064. A similarity of at least 
96  % can be shown for all members of the third group. 
The biggest similarity-99  %- was detected between 
ST21, ST11064 and ST11703. A 98 % similarity between 
Table 1 Incidence of sequence types, porB and tbpB allels 
among azithromycin-resistant or intermediate-resistant N. 
gonorrhoeae strains isolated in Hungary in 2014







10081 5921 29 1 1 –
10083 3031 29 1 1 –
995 28 29 2 – 2
4417 2707 894 3 1 2
10087 35 29 1 – 1
5333 3229 137 1 – 1
225 4 4 1 – 1
10088 2700 4 1 1 –
11706 1183 1388 1 – 1
7232 1489 1388 1 – 1
11702 6870 1582 1 1 –
8706 35 1582 1 1 –
11704 6871 2003 1 – 1
11708 1183 18 1 – 1
8465 4864 18 1 – 1
2400 1489 563 1 – 1
8115 3942 563 1 – 1
11707 4864 563 1 – 1
10101 4160 110 1 1 –
8517 1142 1531 2 1 1
3378 2043 110 1 1 –
8826 5213 110 1 – 1
1407 908 110 5 2 3
11699 6867 138 1 1 –
21 14 33 1 – 1
11064 14 1131 5 2 3
11703 1582 1131 1 1 –
10593 581 1131 1 1 –
11700 6868 1131 1 1 –
4995 3031 33 5 3 2
5343 6195 1131 1 – 1
11337 6630 1131 1 – 1
11705 6872 2004 1 1 –
11701 6869 1131 1 – 1
∑= 50 21 29
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ST11703 and ST10593, or between ST10593 and 
ST11700 was detected, but ST11700 and ST11703 dem-
onstrated only a 97 % similarity. With the latter two STs, 
ST4995 showed a similarity of 96  %. Between ST 4995 
and ST5343 or ST11337 a similarity of 97 % was detected.
Discussion
For the treatment of gonorrhoea, the European Guide-
line, published in 2012, recommends 500  mg of ceftri-
axone combined with 2 g of azithromycin as first choice 
therapy [2]. This dual therapy is supported by European 
epidemiological surveys, mostly based on western Euro-
pean data. These European epidemiological surveys dem-
onstrate that C. trachomatis co-infection is so common 
in young heterosexual patients under 30 and in MSM 
with gonorrhoea that 1  g of azithromycin administered 
orally as a single dose or 100 mg of doxycycline adminis-
tered orally twice daily for 7 days should be given unless 
co-infection has been excluded by NAAT testing.
Since resistance to azithromycin increased from 0 to 
30  % in Hungary in the last 5  years, and WHO recom-
mended [1] that an antimicrobial should not be used 
when >5 % of the strains are resistant, we aimed to con-
duct an active surveillance to detect recent emergence 
in Hungary. Our theory for the increasing azithromycin 
resistance is that, according to ESAC, azithromycin has 
become the second most commonly used antimicrobial 
in Hungary. Hence, patients might have been treated 
previously with azithromycin for an infection, microbi-
ome in the pharynx or anus, could have been exposed to 
this antibiotic several times, could have acquired resist-
ance and acted as reservoirs of genes [12]. Azithromy-
cin-resistant samples were frequently isolated from the 
pharynx (21 %) or the anus (32.5 %), which may refer to 
the fact that the asymptomatic carrier state provides an 
opportunity for commensal microbiome and N. gonor-
rhoeae to exchange their resistance genes, resulting in a 
hyperexpression of the efflux pump MtrCDE or mutation 
in the 23S rRNA [13, 14]. The high percentage of infec-
tions in the pharynx and anus do not only involve the risk 
of acquiring resistance, but also the risk of developing a 
disseminated infection and the spread of asymptomatic 
gonorrhoea.
Previously, the most frequent isolated STs were 
ST2992, ST1407, ST4995 and ST225 in Hungary [15]. 
In our recent study, three groups of STs based on closer 
relationship, were observed among azithromycin-resist-
ant or intermediate-resistant N. gonorrhoeae strains iso-
lated in Hungary in 2014. The first group contains the 
previously described ST225; ST1407 belongs to the sec-
ond group, while ST4995 and ST11064 are included in 
the third group (Fig. 1). The latter two STs represent the 
20 % of the azithromycin-resistant strains but, according 
to the data of Table 1 and Fig. 1, it can be presumed that 
more than 30 % of the azithromycin-resistant isolates are 
closely related in the third group of STs (similarity is at 
least 96 %). The previously described uniquely high prev-
alence of ST4995 in Hungary confirms the theory that 
the isolates of the third neighbourhood group are suc-
cessful strains in this country, and may cause therapeutic 
failure in our region in the future. Nevertheless, based on 
the exact definition of genogroup—one identical allele is 
shared and the other allele shows a similarity of ≥99  % 
[16]—only ST21, ST11064 and ST11703 make up a geno-
group. This genogroup is named G11064, since ST11064 
is the predominant ST within the group.
The other prevalently isolated strains in the second 




































Fig. 1 Phylogenic tree constructed from porB and tbpB allels (ST) 
from 50 azithromycin‑resistant or intermediate‑resistant strains 
isolated in 2014 in Hungary. Number of isolates according to the 
appropriate STs is indicated in parenthesis
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the ST previously described as resistant to ciprofloxacin, 
tetracycline and strongly associated with decreased sus-
ceptibility to cephalosporins [16, 17]. Poorly controlled 
use of antibiotics may promote the selection and spread 
of multidrug-resistant strains from this group [18].
The rapid selection of azithromycin-resistant strains 
in Hungary shows that azithromycin might not be 
optimised for the treatment of gonorrhoea, neither in 
monotherapy nor in dual therapy. On the one hand, the 
question is whether the combination of cephalosporins 
with azithromycin decreases the MICs of cephalospor-
ins or not. There are some studies which report in vitro 
synergy between third-generation cephalosporins and 
azithromycin [19], but others do not [20]. The clinical 
efficacy of the dual therapy with ceftriaxone and azithro-
mycin could be lower than ceftriaxone monotherapy 
since the combination was less bactericidal as ceftriaxone 
alone in a time-kill experiment [21].
On the other hand, we have to investigate the preva-
lence of C. trachomatis co-infection. In Europe, accord-
ing to ECDC’s data, Chlamydia is the most frequently 
reported STD. In 2011, 346911 cases were notified in 25 
European countries, and 39179 cases of gonorrhoea were 
registered. By contrast, in our laboratory twice as many 
gonorrhoea infections were identified as Chlamydia 
infections; 6.7 % of the samples of the STD centre were 
Chlamydia-positive and 12.2  % were gonorrhoea-posi-
tive. These data correlate with those of the National Epi-
demiological Laboratory, where 1077 cases of Chlamydia 
and 1525 cases of gonorrhoea were recorded in 2013. 
While the surveys of IUSTI refer to the common preva-
lence of co-infection, in our laboratory only 14.7 % of the 
gonorrhoea-positive samples were co-infected with C. 
trachomatis. This also raises the question whether com-
bination therapy is the appropriate treatment in Hungary 
for gonorrhoea infection. Furthermore, as the increasing 
azithromycin-resistance and also the emerging cefixime 
and ceftriaxone MICs threaten the currently recom-
mended therapies for gonorrhoea, it would be essential 
to replace these antimicrobials with novel ones which 
have not been used before for gonorrhoea infection in 
our country. The use of solithromycin, gentamicin, gemi-
floxacin might be a short term solution, but developing 
novel antimicrobials is essential [22, 23].
Conclusions
In Hungary, the treatment of gonorrhoea infections relies 
on the combination therapy of ceftriaxone and azithro-
mycin, recommended by the international guidelines. 
However, the data of this study should not only draw 
attention to caution in the use of azithromycin as the sole 
treatment for gonorrhoea but also to that in the use of 
combination therapy in Hungary. This study indicates 
that the rate of azithromycin-resistant strains is growing 
in our country year by year. We observed a unique emer-
gence of azithromycin-resistant N. gonorrhoeae strains 
the amount of which has doubled in a period of 1e year. 
Besides, the strains being the most common in Hungary 
in 2013, also appeared in 2014 and were associated with 
azithromycin-resistance. This experience restricts the 
usefulness of this antibiotic recommended as first-line 
treatment for gonorrhoea worldwide and argues for regu-
lar surveillance to determine azithromycin-susceptibility.
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